Compare Recursion Pharmaceuticals Inc (RXRX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TotalEnergies SE — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.31B), while TotalEnergies SE trades at $86.07 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 83× Recursion Pharmaceuticals Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and TotalEnergies SE for 90 Days on average.
| RXRX | TTE | |
|---|---|---|
Market Cap | $2.31B | $191.82B |
Volume | 40,478,768 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $6.79 | $93.60 |
52-Week Low | $2.84 | $57.39 |
Typical Hold Time | 22 Days | 90 Days |
Enterprise Value | $1.83B | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 10.54 and P/S of 0.94. Recent earnings beat expectations in Q1 and Q2 2026, though revenue has declined from 2022 peaks. The company maintains a strong cash flow profile and has announced a $10 billion investment in Argentina, alongside a commitment to grow dividends by 5% annually through 2030.
The outlook is supported by strategic expansions in LNG and power, but risks include volatile energy prices and execution of capital projects. Analyst consensus is bullish with a $95.33 price target, implying potential upside. Investors should weigh the company's solid fundamentals and shareholder returns against sector-specific headwinds and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
